前列腺素E1对比安慰剂治疗进行性系统性硬化症伴严重雷诺现象患者的疗效评估
Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
作者信息
Bartolone S, Trifiletti A, De Nuzzo G, Scamardi R, Larosa D, Sottilotta G, Raffa A, Barbera N
机构信息
Department of Internal Medicine, University of Messina.
出版信息
Minerva Cardioangiol. 1999 May;47(5):137-43.
BACKGROUND
Raynaud's phenomenon, due to connective tissue diseases, is difficult to treat successfully. Symptomatic improvement has been reported using nifedipine or iloprost, but adverse side effects may limit their use. The purpose of this study was to examine the effects of PGE1 (Alprostadil) in patients with scleroderma and severe Raynaud's disease.
METHODS
Twelve females, aged 50-67 years, were included in the study with six of them receiving a 3-hour infusion of alprostadil at the standard dosage of 60 micrograms in 250 cc of physiological infusion for six consecutive days and the remaining six receiving placebo (250 cc of physiological infusion administered in the same manner).
RESULTS
After infusion, blood flow, digitally measured by telethermography was increased only in patients treated with alprostadil. The number, frequency and severity of attacks recorded were reduced only in patients treated with alprostadil. No side effects were recorded during and after the infusion.
CONCLUSION
In conclusion, alprostadil is effective in the management of Raynaud's phenomenon, due to scleroderma.
背景
由结缔组织疾病引起的雷诺现象难以成功治疗。据报道，使用硝苯地平或伊洛前列素可改善症状，但不良反应可能限制其使用。本研究的目的是研究前列地尔（前列腺素E1）对硬皮病和重度雷诺病患者的影响。
方法
12名年龄在50至67岁之间的女性纳入本研究，其中6名连续6天接受标准剂量60微克前列地尔在250毫升生理盐水中进行3小时的输注，其余6名接受安慰剂（以相同方式给予250毫升生理盐水）。
结果
输注后，仅前列地尔治疗的患者通过远红外热像仪数字测量的血流增加。记录的发作次数、频率和严重程度仅在前列地尔治疗的患者中减少。输注期间及之后未记录到副作用。
结论
总之，前列地尔对硬皮病引起的雷诺现象有效。
Zotero 插件